嗜黏蛋白阿克曼菌在非酒精性脂肪性肝病中的作用
Role of Akkermansia muciniphila in nonalcoholic fatty liver disease
郑立婷 1汪哲 1陈玉春 2刘珊山 1解有成 1李初谊 2于晓辉2
作者信息
- 1. 中国人民解放军联勤保障部队第九四〇医院消化内科,兰州 730050;甘肃中医药大学第一临床医学院,兰州 730000
- 2. 中国人民解放军联勤保障部队第九四〇医院消化内科,兰州 730050
- 折叠
摘要
非酒精性脂肪性肝病(NAFLD)已成为全球最常见的慢性肝病,同时也是发生肝硬化和肝细胞癌的主要原因之一,因此及时遏止NAFLD的发生发展尤为重要,但由于其复杂的发病机制,目前尚无有效的根治手段.嗜黏蛋白阿克曼菌(Akk菌)作为新一代益生菌,能够改善机体代谢紊乱.越来越多的研究表明,Akk菌对代谢性疾病,尤其是NAFLD有潜在的治疗作用.因此,本文就Akk菌在NAFLD中的作用机制作简要综述,旨在为NAFLD的治疗改进和开创新疗法提供新思路.
Abstract
Nonalcoholic fatty liver disease(NAFLD)has become the most common chronic liver disease in the world,and it is also one of the main causes of liver cirrhosis and hepatocellular carcinoma,so it is particularly important to curb the development and progression of NAFLD in a timely manner.However,due to its complex pathogeneses,there are currently no effective methods for radical treatment.As a new generation of probiotics,Akkermansia muciniphila(Akk bacteria)can improve metabolic disorders of the body,and more and more studies have shown that Akk bacteria have a potential therapeutic effect on metabolic diseases,especially NAFLD.Therefore,this article briefly reviews the mechanism of action of Akk bacteria in NAFLD,in order to provide new ideas for improving the treatment of NAFLD and creating new therapies.
关键词
非酒精性脂肪性肝病/阿克曼菌属/治疗学Key words
Non-alcoholic Fatty Liver Disease/Akkermansia/Therapeutics引用本文复制引用
基金项目
甘肃省非感染性肝病临床医学研究中心(21JR7RA017)
联勤保障部队第九四〇医院肝病临床医学研究中心(2021yxky079)
甘肃省卫健委科研管理项目(GSWSKY2021-047)
出版年
2024
国家科技期刊平台
NSTL
万方数据